ReviewHealth physics2015
Medical Countermeasures for Radiation Exposure and Related Injuries: Characterization of Medicines, FDA-Approval Status and Inclusion into the Strategic National Stockpile.
Review in Health physics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 140 citations in OpenAlex.
- Oral connexin43-peptide-loaded milk extracellular vesicles mitigate lethal radiation injury while preserving tumour radiosensitivity.Cancer letters · 2026Article
- Experimental assessment of radioprotective efficiency of Rhizoplaca chrysoleuca (Sm.) Zopf extract against uranyl nitrate hexahydrate.Scientific reports · 2026Article
- Optimized Monothiol Thioredoxin Derivative (ORP100S) Protects In Vitro and In Vivo from Radiation and Chemotoxicity Without Promoting Tumor Proliferation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- DSUP modified mesenchymal stem cells exert significant radiation protective effect by enhancing the hematopoietic niche.Stem cell research & therapy · 2025Article
- Cannabidiol restores hematopoietic stem cell stemness in mouse through Atf2-Lrp6 axis after acute irradiation.MedComm · 2025Article
- IEPA, a novel radiation countermeasure, alleviates acute radiation syndrome in rodents.International journal of radiation biology · 2025Article
- Imidazolyl ethanamide pentandioic acid promotes hematopoietic recovery following sublethal radiation in a murine model.International journal of radiation biology · 2025Article
- The potential longevity-promoting hypoxic-hypercapnic environment as a measure for radioprotection.Biogerontology · 2024Review
- Dehydroepiandrosterone and Its Metabolite 5-Androstenediol: New Therapeutic Targets and Possibilities for Clinical Application.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Review
- Cell Therapies for Acute Radiation Syndrome.International journal of molecular sciences · 2024Review
- Radiation and Chemical Program Research for Multi-Utility and Repurposed Countermeasures: A US Department of Health and Human Services Agencies Perspective.Disaster medicine and public health preparedness · 2024Article
- Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects.Antioxidants (Basel, Switzerland) · 2023Review
- The role of bacteria and its derived biomaterials in cancer radiotherapy.Acta pharmaceutica Sinica. B · 2023Review
- Development of radiation countermeasure agents for acute radiation syndromes.Animal models and experimental medicine · 2023Review
- Nanodrugs with intrinsic radioprotective exertion: Turning the double-edged sword into a single-edged knife.Exploration (Beijing, China) · 2023Review
- Discovery of the radio-protecting effect of Ecliptae Herba, its constituents and targeting p53-mediated apoptosisActa pharmaceutica Sinica. B · 2023Article
- The delayed effects of acute radiation exposure (DEARE): characteristics, mechanisms, animal models, and promising medical countermeasures.International journal of radiation biology · 2023Review
- A Review of Radiation-Induced Alterations of Multi-Omic Profiles, Radiation Injury Biomarkers, and Countermeasures.Radiation research · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
World events over the past decade have highlighted the threat of nuclear terrorism as well as an urgent need to develop radiation countermeasures for acute radiation exposures and subsequent bodily injuries. An increased probability of radiological or nuclear incidents due to detonation of nuclear weapons by terrorists, sabotage of nuclear facilities, dispersal and exposure to radioactive materials, and accidents provides the basis for such enhanced radiation exposure risks for civilian populations. Although the search for suitable radiation countermeasures for radiation-associated injuries was initiated more than half a century ago, no safe and effective radiation countermeasure for the most severe of these injuries, namely acute radiation syndrome (ARS), has been approved by the United States Food and Drug Administration (FDA). The dearth of FDA-approved radiation countermeasures has prompted intensified research for a new generation of radiation countermeasures. In this communication, the authors have listed and reviewed the status of radiation countermeasures that are currently available for use, or those that might be used for exceptional nuclear/radiological contingencies, plus a limited few medicines that show early promise but still remain experimental in nature and unauthorized for human use by the FDA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.